Rheumatoid Arthritis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Rheumatoid Arthritis – Pipeline Review, H1 2020’, provides an overview of the Rheumatoid Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis

– The report reviews pipeline therapeutics for Rheumatoid Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Rheumatoid Arthritis therapeutics and enlists all their major and minor projects

– The report assesses Rheumatoid Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

4D Pharma Plc

AB Science SA

AbbVie Inc

AbClon Inc

Abivax SA

Ablynx NV

ACEA Therapeutics Inc

Acelerox LLC

Aclaris Therapeutics Inc

Aevi Genomic Medicine Inc

Affilogic SAS

Agency for Science, Technology and Research

Agragen LLC

Ahead Therapeutics SL

Aibios Co Ltd

AimVion AS

Akari Therapeutics Plc

Alibion AG

Allied-Bristol Life Sciences LLC

Allosterix Ltd

Alphamab Oncology

Alpine Immune Sciences Inc

Aluda Pharmaceuticals Inc

Alvotech ehf

Amgen Inc

Amrif BV

Anew Oncology Inc

AnTolRx Inc

Apaxen

Apcegen Technologies Pvt Ltd

Apitope International NV

Applied Genetic Technologies Corp

Aprogen Inc

Archigen Biotech Ltd

arGentis Pharmaceuticals LLC

Argenx SE

Arrien Pharmaceuticals LLC

Arthrogen BV

Asahi Kasei Pharma Corp

Astellas Pharma Inc

AstraZeneca Plc

Atlanthera

Atlantic Bio Sci LLC

Auransa Inc

Aurigene Discovery Technologies Ltd

Axsome Therapeutics Inc

Axxam SpA

Bausch Health Companies Inc

Bayer AG

Baylx Inc

Beijing Eastern Biotech Co Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Beijing VDJBio Co Ltd

Bio-Cancer Treatment International Ltd

Bio-Thera Solutions Ltd

Biocad

Biocon Ltd

Biogen Inc

Bioiberica SAU

Biois Corp

BioLingus AG

BioLite Inc

Biosion Inc

Biotech Holdings

BioXpress Therapeutics SA

Biozeus Pharmaceutical SA

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

BTB Pharma AB

c-a-i-r Biosciences GmbH

C4X Discovery Holdings Plc

Can-Fite BioPharma Ltd

CannBioRex Pharmaceuticals Corp

Carna Biosciences Inc

CEL-SCI Corp

Cellinbio Co Ltd

Celltrion Inc

Cellworks Group Inc

CHA Bio & Diostech Co Ltd

CheckPoint Immunology Inc

Chipscreen Biosciences Ltd

ChironWells GmbH

Chong Kun Dang Pharmaceutical Corp

Citryll BV

CJ HealthCare Corp

Clevexel Pharma SAS

Clover Biopharmaceuticals

Coherus BioSciences Inc

Commence Bio Inc

Compugen Ltd

Cour Pharmaceuticals Development Co Inc

Crossject SA

CSL Ltd

CV6 Therapeutics (Ni) Ltd

Cyclacel Pharmaceuticals Inc

Cytocom Inc

Cyxone AB

Daewoong Pharmaceutical Co Ltd

DeMay Biotech

Denali Therapeutics Inc

Dendright Pty Ltd

Diamyd Medical AB

DiNonA Inc

DM Bio Ltd

DNX Biopharmaceuticals Inc

Domainex Ltd

Dr. Reddy's Laboratories Ltd

Ducentis BioTherapeutics Ltd

Dynavax Technologies Corp

Eisai Co Ltd

Enzene Biosciences Ltd

Enzychem Lifesciences Corp

Ergon Pharmaceuticals LLC

Eternity Bioscience Inc

Eton Pharmaceuticals Inc

Evelo Biosciences Inc

Fresenius SE & Co KGaA

Fujifilm Kyowa Kirin Biologics Co Ltd

Galapagos NV

Gene Techno Science Co Ltd

GeneFrontier Corp

Genentech Inc

Generium

GeneScience Pharmaceuticals Co Ltd

Genfit SA

Genor BioPharma Co Ltd

Genosco Inc

Genova Biotech Company Ltd

Genrix (Shanghai) Biopharmaceutical Co Ltd

Gismo Therapeutics Inc

GlaxoSmithKline Plc

GNT Biotech and Medicals Corp

GNT Pharma Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd

Guangzhou BeBetter Medicine Technology Co Ltd

Han Wha Pharma Co Ltd

Hana Pharm Co Ltd

Hangzhou East China Pharmaceutical Group Co Ltd

Hanlim Pharm Co Ltd

Hebei Fitness Biotechnology Co Ltd

HEC Pharm Co Ltd

Hengenix Biotech Inc

HitGen LTD

Hope Biosciences LLC

HSRx Group

Huabo Biopharm Co Ltd

Hualan Biological Engineering Inc

Humabs BioMed SA

HuniLife Biotechnology Inc

Hutchison MediPharma Ltd

I-Mab Biopharma Co Ltd

iBio Inc

Ichnos Sciences Inc

ID Pharma Co Ltd

Idogen AB

IL-2Rx Inc

ImCyse SA

Immune Regulation Ltd

Immungenetics AG

ImmunoPrecise Antibodies Ltd

Immunwork Inc

Immutep Ltd

Impetis Biosciences Ltd

InflammatoRx inc

Innate Pharma SA

Innovent Biologics Inc

Innovimmune Biotherapeutics Inc

InSight Biopharmaceuticals Ltd

Istesso Ltd

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

JiangSu Qyuns Therapeutics Co Ltd

Jinyu Bio-technology Co Ltd

Johnson & Johnson

Jubilant Biosys Ltd

Jyant Technologies Inc

Kadmon Corp LLC

Kang Stem Biotech Co Ltd

KBP BioSciences Co Ltd

Kemmx Corp

Kezar Life Sciences Inc

KIMS Pharmaceutical Co Ltd

Kine Sciences

L2 Diagnostics LLC

Landos Biopharma Inc

Lead Pharma Holding BV

Leukosight Inc

LG Chem Ltd

LipUm AB

LISCure Biosciences Co Ltd

Livzon MabPharm Inc

Lupin Ltd

Mabion SA

Mabpharm Ltd

Mabtech Ltd

mAbxience SA

Maruho Co Ltd

MedAnnex Ltd

MENTRIK Biotech LLC

Merck & Co Inc

Merck KGaA

Mesoblast Ltd

MetiMedi Pharmaceuticals Co Ltd

MetrioPharm AG

Microbiotix Inc

Millennium Pharmaceuticals Inc

Mirae Cell Bio Co Ltd

Momenta Pharmaceuticals Inc

Moogene Medi Inc

Mycenax Biotech Inc

MyeloRx LLC

Nascient Ltd

Navigen Inc

NeuClone Pty Ltd

Neuracle Science Co Ltd

Nichi-Iko Pharmaceutical Co Ltd

Nissan Chemical Corp

NovalGen Ltd

Novartis AG

NovImmune SA

NuBioPharma LLC

Numab Innovation AG

Octagon Therapeutics Inc

Omeros Corp

Oncodesign SA

OncoImmune Inc

Oneness Biotech Co Ltd

Orbis Biosciences Inc

Oryn Therapeutics

OSE Immunotherapeutics

Pahan Therapeutics

Paras Biopharmaceuticals Finland Oy

Peptinov SAS

Pfizer Inc

Pharmapraxis

Philogen SpA

Promethera Biosciences SA

ProNoxis AB

Protab Ltd

Protalex Inc

Protheragen Inc

Qu Biologics Inc

R Pharm

Radikal Therapeutics Inc

Reata Pharmaceuticals Inc

ReceptoPharm Inc

RedHill Biopharma Ltd

Regen BioPharma Inc

Regenerative Arthritis & Bone Medicine Inc

Reliance Life Sciences Pvt Ltd

RemeGen Ltd

Resverlogix Corp

ReveraGen BioPharma Inc

Rhizen Pharmaceuticals SA

Ribomic Inc

Richter Gedeon Nyrt

Rigel Pharmaceuticals Inc

Rophibio Inc

ROS Therapeutics ApS

Rottapharm Biotech Srl

Saje Pharma LLC

Sareum Holdings Plc

SBI Biotech Co Ltd

Sengenics International Pte Ltd

Serene LLC

Servatus Ltd

Shandong Danhong Pharmaceutical Co Ltd

Shanghai Biomabs Pharmaceuticals Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shanghai Pharmaceutical Co Ltd

Siam Bioscience Co Ltd

Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd

Signablok Inc

Simcere Pharmaceutical Group

Singh Biotechnology LLC

Sino Biopharmaceutical Ltd

Sinocelltech Ltd

SinoMab Bioscience Ltd

SomaLogic Inc

Splash Pharmaceuticals Inc

Suntec Medical (Taiwan) Inc

Suzhou Connect Biopharmaceuticals Ltd

Suzhou Ribo Life Sciences Co Ltd

Suzhou Sinovent Pharmaceuticals Co Ltd

SynAct Pharma AB

Synermore Biologics Co Ltd

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Tasly Pharmaceutical Group Co Ltd

TG Therapeutics Inc

Tiziana Life Sciences Plc

Toleranzia AB

Tonix Pharmaceuticals Holding Corp

TPCera Ltd

Translational Biosciences

Tumorend LLC

Turgut Ilaclari AS

Twoxar Inc

UCB SA

United BioPharma Inc

Vaccinex Inc

Vascular Biogenics Ltd

Viela Bio Inc

Voronoi

Wuhan Institute of Biological Products Co Ltd

Wuxi Fuxin Pharmaceutical Research and Development Co Ltd

X-Rx Inc

Xalud Therapeutics Inc

Xbrane Biopharma AB

Xencor Inc

XL-protein GmbH

Y-Biologics Inc

Yichang Humanwell Pharmaceutical Co Ltd

Yuhan Corp

Yungjin Pharm Co Ltd

Zhejiang Hisun Pharmaceutical Co Ltd

Zumutor Biologics Inc

ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Rheumatoid Arthritis - Overview

Rheumatoid Arthritis - Therapeutics Development

Rheumatoid Arthritis - Therapeutics Assessment

Rheumatoid Arthritis - Companies Involved in Therapeutics Development

Rheumatoid Arthritis - Drug Profiles

Rheumatoid Arthritis - Dormant Projects

Rheumatoid Arthritis - Discontinued Products

Rheumatoid Arthritis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Rheumatoid Arthritis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Rheumatoid Arthritis – Pipeline by 3SBio Inc, H1 2020

Rheumatoid Arthritis – Pipeline by 4D Pharma Plc, H1 2020

Rheumatoid Arthritis – Pipeline by AB Science SA, H1 2020

Rheumatoid Arthritis – Pipeline by AbbVie Inc, H1 2020

Rheumatoid Arthritis – Pipeline by AbClon Inc, H1 2020

Rheumatoid Arthritis – Pipeline by Abivax SA, H1 2020

Rheumatoid Arthritis – Pipeline by Ablynx NV, H1 2020

Rheumatoid Arthritis – Pipeline by ACEA Therapeutics Inc, H1 2020

Rheumatoid Arthritis – Pipeline by Acelerox LLC, H1 2020

Rheumatoid Arthritis – Pipeline by Aclaris Therapeutics Inc, H1 2020

Rheumatoid Arthritis – Pipeline by Aevi Genomic Medicine Inc, H1 2020

Rheumatoid Arthritis – Pipeline by Affilogic SAS, H1 2020

Rheumatoid Arthritis – Pipeline by Agency for Science, Technology and Research, H1 2020

Rheumatoid Arthritis – Pipeline by Agragen LLC, H1 2020

Rheumatoid Arthritis – Pipeline by Ahead Therapeutics SL, H1 2020

Rheumatoid Arthritis – Pipeline by Aibios Co Ltd, H1 2020

Rheumatoid Arthritis – Pipeline by AimVion AS, H1 2020

Rheumatoid Arthritis – Pipeline by Akari Therapeutics Plc, H1 2020

Rheumatoid Arthritis – Pipeline by Alibion AG, H1 2020

Rheumatoid Arthritis – Pipeline by Allied-Bristol Life Sciences LLC, H1 2020

Rheumatoid Arthritis – Dormant Projects, H1 2020

Rheumatoid Arthritis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Rheumatoid Arthritis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports